PMOS, PCOS, and GLP-1 pregnancy planning

Pregnancy can be possible despite irregular periods or PCOS. Discuss recent sexual activity, contraception, the last period and whether testing is needed before treatment. Weight-loss medicines should not be used for weight treatment during pregnancy. Do not assume that infrequent cycles or a prior fertility difficulty excludes pregnancy.

Tell the prescriber the planned pregnancy timeline before choosing weight treatment. It affects whether a medicine is suitable now and when it should stop; semaglutide weight treatment needs at least a two-month interval before planned pregnancy. Review the exact product, contraception and alternative care rather than begin treatment without a preconception plan.

Identify the exact medicine and the goal it is meant to address: glucose, weight, cycle symptoms or fertility. These uses have different evidence, labels and monitoring. Ask whether the proposed use is approved or off label, how benefit will be checked and how it fits pregnancy plans; a drug name alone does not define the care plan.

Yes, cycle patterns can change with metabolic changes or treatment, but the direction and timing vary. Track bleeding and discuss a persistent change with the clinician. Irregular periods do not reliably prevent pregnancy; review contraception and pregnancy plans. A change in cycles does not prove that infertility has been treated.

Fertility evaluation may involve an obstetrician-gynecologist or reproductive specialist, depending on the concern and prior treatment. Confirm Nao’s actual evaluation and referral scope before booking. Weight or metabolic care can support health, but it does not establish a complete infertility service or guarantee pregnancy.

If a pregnancy test is positive while using a weight-loss medicine, contact the prescriber promptly for the product-specific stopping and care plan. Weight treatment should not continue during pregnancy. Review the exact medicine, last dose and other treatments with the pregnancy-care team; do not interpret the result only as evidence that fertility improved.

Weight-loss medicines are not appropriate for weight treatment during pregnancy. Tell the prescriber promptly if pregnancy occurs or is planned. Semaglutide for weight treatment should be stopped at least two months before a planned pregnancy. Tirzepatide and Foundayo need product-specific planning and contraception review. Pregnancy and breastfeeding advice must use the exact label.

For planned pregnancy, the Wegovy label advises stopping at least two months beforehand because semaglutide remains in the body for a prolonged period. Discuss the stopping date and alternative care with the prescriber. If pregnancy occurs, contact the treating team promptly; weight treatment should not continue during pregnancy.

Tirzepatide can reduce oral contraceptive reliability. Switch to a non-oral method or add a barrier method for four weeks after starting and four weeks after each dose increase. Irregular cycles do not mean pregnancy is impossible. Discuss the plan before treatment.

Metabolic or weight changes may affect cycles and ovulation, but response varies and pregnancy is not guaranteed. Irregular cycles do not prevent pregnancy reliably. Review contraception and pregnancy goals with the clinician. GLP-1 weight-loss treatment is not an approved infertility treatment.

Irregular periods need assessment and do not reliably prevent pregnancy. Review the pattern, pregnancy possibility, other symptoms and your goals with the clinician. PCOS-related cycle care, contraception and fertility treatment may need different plans; do not assume a weight medicine alone will address the cause or make pregnancy safe.

Restarting requires review of breastfeeding, future pregnancy plans, your current health, and how long treatment was interrupted. Do not resume the old dose automatically. Tablet and injection breastfeeding recommendations differ. Ask the prescriber to choose an appropriate restart plan.

Confirm whether the selected Nao clinician evaluates the fertility concern or refers to an obstetrician-gynecologist or reproductive specialist. Infertility investigation and ovulation treatment are different from weight-management prescribing. Bring cycle, pregnancy and prior treatment records so the appropriate care can be arranged.

There is no single stop-or-continue rule for everyone with PCOS. Tell the maternity team why you take metformin and review the plan with the prescriber; treatment for established diabetes is a different decision from use for PCOS alone. The international PCOS guideline says metformin in pregnant patients with PCOS has not been shown to prevent gestational diabetes, late miscarriage, pregnancy hypertension, pre-eclampsia or a large baby. It may be considered in selected circumstances, such as risk of preterm birth, but long-term effects on children remain uncertain. Do not assume it replaces pregnancy glucose testing or automatically stop a diabetes treatment without an alternative plan. Coordinate medication review, nutrition and glucose monitoring with the pregnancy-care team.